• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » sBioMed taps ex-Stryker CEO MacMillan as CEO

sBioMed taps ex-Stryker CEO MacMillan as CEO

November 1, 2012 By Brad Perriello

sBioMed CEO Stephen MacMillan

Former Stryker (NYSE:SYK) CEO Stephen MacMillan, whose sudden ouster from the medical device company earlier this year shocked medtech, tells MassDevice.com that he has a new gig: CEO and part-owner of sBioMed, which makes an anti-infection agent called Steriplex SD.

We spoke with a relaxed-sounding MacMillan last week from his new base in Orem, Utah, where SBioMed has its headquarters. In a wide-ranging chat, he told us about the wrenching separation from Stryker, how he adjusted to "civilian life" and what’s behind his latest move.

Sign up to get our free newsletters delivered right to your inbox

The impetus to join sBioMed came from a desire to find a business opportunity that would have a meaningful impact on healthcare, MacMillan told us. Eight-year-old sBioMed says the Steriplex SD solution kills clostridium difficile, a healthcare-associated infection that’s named for its notorious hardiness. Citing "user-friendly chemistries," the company says its "non-fuming and non-corrosive" formula is a green alternative to bleach.

"After a decade of research, over 500 studies and EPA registration, we are excited to enter the full-scale commercialization process. With Steve’s leadership, we can help eliminate healthcare-associated infections globally," sBioMed co-founder and chairman Brian Larson said in prepared remarks.

MacMillan told us that the potential market for the product goes far beyond the multi-billion-dollar hospital market.

"There are also enormous opportunities for this product in the animal health world, in the hospitality world, restaurants, hotels, big in the agriculture world, pharmaceutical clean rooms. There are a whole bunch of markets beyond just the core hospital market," he said. "Ultimately I think there is a big consumer angle. What I see is the chance to build a major significant company that is doing some good for the world."

MacMillan declined to specify just how large a stake he acquired in sBioMed, saying only that it was "significant" and "meaningful."

MacMillan resigned from Stryker Feb. 8, citing family reasons, sending shock waves throughout the medical device world. Rumors soon surfaced that his ouster was due to board members’ consternation over his relationship with an ex-employee; it later emerged that MacMillan had sought the board’s approval after his divorce was final and before he began the relationship.

Asked about his very public departure and the attention to his personal life, MacMillan termed his ouster "unfair."

"There are a lot of great people at Stryker. I think my exit was an unfortunate and unfair experience. To me it was unfair, unfortunate and personally challenging," he told us. "My exit was not precipitated by any unethical or poor behavior. Yet it appeared that way, and that was very difficult to deal with, for both me and my family."

Relations with the board were touchy at the outset, as MacMillan was relatively young to helm a major public company (he was named president & COO at 39 and took over the corner office at 41). He was also replacing John Brown, whom MacMillan called "a legend," after 3 decades as CEO.

"As a younger, hard-charging person dramatically changing a company, to adjust it to the new realities, you build some scar tissue with board members," he explained. "We then had to go through a lot of significant changes, the regulatory environment change, we had to move away from delivering 20% earnings growth. We had to make some changes to some of the board structures.

"Then when you start to change over the board and ask a few long-serving people to step down, bring some new ones on, it can create some very difficult dynamics in the boardroom. I think I built up some scar tissue and there became a convenient reason for some members of the board to lose some confidence in me. That just is not a fun environment to operate in."

That said, MacMillan seemed relaxed and energized by his new situation in Utah and fond of his time at Stryker, despite its ugly end.

"I am remarkably proud of what we accomplished at Stryker. During the years I was there, we tripled the revenues, we diversified the business, we dramatically enhanced the quality in manufacturing operations. That’s a real testimony to the strength of the employee base. That’s not the result of any 1 person, but I am very proud of so much of what we did there, still very proud of the employees and company."

Filed Under: News Well Tagged With: Medical Supplies, Personnel Moves, sBioMed, Stryker

In case you missed it

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance

RSS From Medical Design & Outsourcing

  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy